Summary -

Key Takeaways Explained for a Non-Medical Audience

– Hyperinsulinemia is a hallmark of obesity and is both a result and driver of insulin resistance, perpetuating metabolic dysfunction.

– Elevated insulin levels act directly on cancer-prone cells—especially pancreatic acinar cells—to promote early tumor formation and inflammation.

– Hyperinsulinemia enhances IL‑17–driven inflammation in obesity, facilitating aggressive prostate cancer progression through impaired GSK3‑mediated regulation of IL‑17RA.

– Obesity-associated elevation in insulin supports tumor growth in models of colon and breast cancer by increasing glucose uptake and oxidation in tumor cells.

– Interventions that lower insulin—such as ketogenic low-carbohydrate diets, metformin, or SGLT2 inhibitors—can suppress tumor growth and metabolic dysfunction.

– In nonobese individuals, hyperinsulinemia independently predicts higher cancer-related mortality, underscoring its risk beyond overweight status.

– Insulin stimulates pro-inflammatory NF-κB signaling and cytokine production (e.g., IL-6, TNF-α), promoting an environment conducive to cancer development.

– Insulin and insulin-like growth factor 1 (IGF-1) exert mitogenic effects, supporting malignant cell proliferation and survival.

– Obesity-related organ enlargement, partially driven by hyperinsulinemia, may increase cancer risk by expanding the number of susceptible cells.

– Chronic insulin elevation fosters oxidative stress, vascular dysfunction, and hormone imbalances that collectively support carcinogenesis.

– Targeting insulin signaling pathways offers a promising preventive strategy against obesity-associated cancers.

Hyperinsulinemia contributes to an inflammatory microenvironment through macrophage polarization and cytokine release.

– Insulin-driven metabolic reprogramming may aid tumor survival by enhancing nutrient uptake and energy utilization in malignant tissues.